Award
NIH Reporter #11307042
NAC Attack, A Phase-3, Multicenter, Randomized, Placebo-Controlled Trial in Patients with Retinitis Pigmentosa
Recipient
National Eye Institute (NEI)
Award Amount
$344,858.00
Ceiling
$344,858.00
Awarded
April 09, 2026
Identifier
11307042
This award funds a Phase-3 clinical trial investigating the use of N-acetylcysteine in patients with retinitis pigmentosa to preserve vision and prevent severe visual disability.
Description
A clinical trial for retinitis pigmentosa using N-acetylcysteine to assess the efficacy of NAC in preserving cone cells and preventing severe visual disability. The study involves spectral domain-optical coherence tomography, microperimetry, and whole genome sequencing.